Amplia Therapeutics Ltd (ASX:ATX) CEO Chris Burns joins Proactive’s Jonathan Jackson to discuss the company’s busy quarter and what investors can expect over the coming months. Burns talks us through the completion of the Phase1B stage of the ACCENT clinical trial in advanced pancreatic cancer patients and the promising early signs of drug efficacy that have resulted. The company has now started its Phase2a trial, dosing patients in January. Further to this, there’s also been good news from Korea. Korean drug regulators have approved the company’s application to conduct the ACCENT trial in that country and Korean sites are ready to recruit patients. Finally, Burns discusses an Investigational New Drug application (INDA) submitted to the FDA and what that means for the company moving forward.
Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial
